AI Stock Memo: HIMS - Hims Hers Health - RankAlpha

HIMS

Rating buyAI Memo

Hims Hers Health

As of 2026-02-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-24 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 Earnings & Guidance Update • 2026-05-25

Expected move: -7%

Biggest risk

Disappointing 2026 guidance, rising acquisition costs, or weaker retention compress multiples and push valuation toward the analyst low; downside is most likely if customer economics do not improve.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

Improved CAC, accelerating subscription growth, and material margin expansion drive a re-rating toward the upper half of the analyst range; execution of these levers with consistent quarterly beats would support the bull scenario within a 12-month window.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-24

Base target

$24

p=55%

Bull target

$34

p=25%

Bear target

$13

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Marketing cost optimization and margin recovery
Analyst re-rating toward consensus median as growth stabilizes
Improved CAC, accelerating subscription growth, and material margin expansion drive a re-rating toward the upper half of the analyst range; execution of these levers with consistent quarterly beats would support the bull scenario within a 12-month window.

BearKey bullets

Intense competition in digital consumer health
Regulatory or telehealth policy changes
Rising customer acquisition costs

WatchKey bullets

Q1 2026 Earnings & Guidance Update

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $24 (p=55%)

Bull/Bear spread: +30% / -50%

Vs latest close: Bull +30% · Base -7% · Bear -50%

Scenario probabilities

Bull Target: $34 (p=25%)Base Target: $24 (p=55%)Bear Target: $13 (p=20%)

Commentary

Market tone is mixed: recent headlines note a Q4 EPS beat but emphasize soft 2026 guidance that pressured the stock [#SERP-1]. Analyst coverage shows a wide dispersion (low-to-high spread), signaling divergent views on execution and re-rating potential [#SERP-2]. Near-term sentiment is cautious while longer-term upside depends on margin recovery and retention improvements [#SERP-3].

As of 2026-02-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Disappointing 2026 guidance, rising acquisition costs, or weaker retention compress multiples and push valuation toward the analyst low; downside is most likely if customer economics do not improve.

Drivers

Scannable catalysts and supporting factors

Marketing cost optimization and margin recovery
Analyst re-rating toward consensus median as growth stabilizes

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-24Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$24.23

Range (USD)

$13.00 - $60.00

Count

Query: Hims & Hers Health Inc Class A Common (HIMS) analyst consensus price target high low average

Hims & Hers Health, Inc. (HIMS) Stock Price, News, Quote & History
Search result #1
Hims & Hers Health Inc reported a Q4 earnings beat with EPS of $0.08, but shares are down 52% year-to-date amid soft guidance for 2026.
Open source
Hims & Hers Health Inc. Analyst Estimates - MarketWatch
Search result #2
Stock Price Targets. High, $60.00. Median, $30.50. Low, $13.00. Average, $31.52. Current Price, $15.82. Yearly Numbers. Estimates. HIMS will report 2025 ...
Extracted: $60.00, $30.50, $13.00, $31.52, $15.82Open source
Hims & Hers Health, Inc.: Target Price Consensus and Analysts ...
Search result #3
Analysts' Consensus ; Mean consensus. HOLD ; Number of Analysts. 14 ; Last Close Price. 15.63USD ; Average target price. 27.46USD ; Spread / Average Target. +75.68%.
Extracted: $15.63, $27.46Open source
HIMS Stock Quote Price and Forecast | CNN
Search result #4
Hims & Hers Health, Inc. Class A · Price Momentum Show more. HIMS is trading near the bottom of its 52-week range and below its 200-day simple moving average.
Open source
Hims Hers Health (HIMS) Stock Forecast & Price Target
Search result #5
According to projections from 12 analysts, the average 12-month price target for Hims Hers Health is 27.46, with a high estimate of 48 and a low estimate of 13.
Open source
Hims Hers Health Stock - Displayed [35 Analyst Price Targets]
Search result #6
Highest price target for HIMS is $85, Lowest price target is $21, average price target is $53.25. ... What is HIMS (Hims Hers Health) average time for price ...
Extracted: $85.00, $21.00, $53.25Open source

Scenarios

Bull Target (Scenario probability)

$34 / p=25% prob

Base Target (Scenario probability)

$24 / p=55% prob

Bear Target (Scenario probability)

$13 / p=20% prob

Price $26 as of 2026-05-29

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +30% · Base -7% · Bear -50%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-05-25
Q1 2026 Earnings & Guidance Update
Quarterly results and any guidance revision following a Q4 EPS beat but soft forward commentary; market reaction likely driven by 2026 guidance clarity, subscription metrics, and commentary on CAC and retention [#SERP-1].
Prob 65.00% • Move 30.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Marketing cost optimization and margin recovery
2026-05-25
Execution on customer-acquisition-cost reductions, improved unit economics, and gross-margin expansion could drive a near-term EBITDA inflection; outcome depends on retention and conversion metrics [#SERP-2].
Prob 40% • Move 20% • Priced-in 30%

Long-term Catalysts

Months to a year

Analyst re-rating toward consensus median as growth stabilizes
2027-02-24
If topline growth and margins meet mid-cycle targets, analysts may re-rate shares toward the consensus median/high; this long case is tied to sustained improvement over ~12 months and clearer 2027 cadence [#SERP-2], [#SERP-3].
Prob 35% • Move 120% • Priced-in 25%

Risks

Intense competition in digital consumer health
Regulatory or telehealth policy changes
Rising customer acquisition costs
Weak 2026 guidance or missed quarterly metrics

Peers

Symbol	Summary
TDOC	Teladoc Health, Inc. — telehealth leader with subscription/recurring-care model; comparable on virtual-care demand and recurring-revenue dynamics.
GDRX	GoodRx Holdings, Inc. — consumer-facing healthcare distribution and prescription services; comparable on consumer pricing, Rx fulfillment channels, and digital marketing dependence.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Hims & Hers Health Inc Class A Common (HIMS) analyst consensus price target high low average
Analysis date: 2026-02-24